RxDoctor Payments Data

Elizabeth Nafziger, MD

Neurology · Goshen, INNPI 1699153593

Payments from drug & device makers

$1,964in general payments, 2019–2025

Across 73 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$446
  • Catalyst Pharmaceuticals, Inc.$206
  • UCB, Inc.$182
  • Livanova USA, Inc.$159
  • Biohaven Pharmaceutical Holding Company Ltd.$125
  • Neurelis, Inc.$124
  • plus $722 from 20 others

What the payments were for

  • Food & beverage$1,964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,964 in reported general payments places this provider in the 45th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$528,295
Medicare patients
420
Services billed
18,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$428,463
EpidiolexCannabidiol (Cbd)16$59,243
Nurtec OdtRimegepant Sulfate19$27,890
Aimovig AutoinjectorErenumab-Aooe28$20,936
Emgality PenGalcanezumab-Gnlm27$20,575
FycompaPerampanel14$9,322
Carbidopa-LevodopaCarbidopa/Levodopa308$7,318
Lacosamide38$5,215
Entacapone19$4,566
Carbidopa-Levodopa ErCarbidopa/Levodopa60$3,867
Levetiracetam109$3,167
Dimethyl Fumarate14$2,988
Rivastigmine12$2,020
Memantine Hcl74$1,670
Gabapentin65$1,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$31$428,46326 claims
PfizerNurtec Odt$61$27,89019 claims
Eisai Inc.Fycompa$44$9,32214 claims
Upsher-smith Laboratories LLCTopiramate$24$71761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 308 neurology providers in Indiana.

Other neurology in Goshen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →